387 related articles for article (PubMed ID: 31913492)
1. Incidence, Risk Factors, and Outcomes of Patients Who Develop Mucosal Barrier Injury-Laboratory Confirmed Bloodstream Infections in the First 100 Days After Allogeneic Hematopoietic Stem Cell Transplant.
Dandoy CE; Kim S; Chen M; Ahn KW; Ardura MI; Brown V; Chhabra S; Diaz MA; Dvorak C; Farhadfar N; Flagg A; Ganguly S; Hale GA; Hashmi SK; Hematti P; Martino R; Nishihori T; Nusrat R; Olsson RF; Rotz SJ; Sung AD; Perales MA; Lindemans CA; Komanduri KV; Riches ML
JAMA Netw Open; 2020 Jan; 3(1):e1918668. PubMed ID: 31913492
[TBL] [Abstract][Full Text] [Related]
2. Healthcare Burden, Risk Factors, and Outcomes of Mucosal Barrier Injury Laboratory-Confirmed Bloodstream Infections after Stem Cell Transplantation.
Dandoy CE; Haslam D; Lane A; Jodele S; Demmel K; El-Bietar J; Flesch L; Myers KC; Pate A; Rotz S; Daniels P; Wallace G; Nelson A; Waters H; Connelly B; Davies SM
Biol Blood Marrow Transplant; 2016 Sep; 22(9):1671-1677. PubMed ID: 27311966
[TBL] [Abstract][Full Text] [Related]
3. The burden of mucosal barrier injury laboratory-confirmed bloodstream infection among hematology, oncology, and stem cell transplant patients.
Metzger KE; Rucker Y; Callaghan M; Churchill M; Jovanovic BD; Zembower TR; Bolon MK
Infect Control Hosp Epidemiol; 2015 Feb; 36(2):119-24. PubMed ID: 25632993
[TBL] [Abstract][Full Text] [Related]
4. Mucosal barrier injury laboratory-confirmed bloodstream infection: results from a field test of a new National Healthcare Safety Network definition.
See I; Iwamoto M; Allen-Bridson K; Horan T; Magill SS; Thompson ND
Infect Control Hosp Epidemiol; 2013 Aug; 34(8):769-76. PubMed ID: 23838215
[TBL] [Abstract][Full Text] [Related]
5. A Retrospective Analysis of Bloodstream Infections in Pediatric Allogeneic Stem Cell Transplant Recipients: The Role of Central Venous Catheters and Mucosal Barrier Injury.
Balian C; Garcia M; Ward J
J Pediatr Oncol Nurs; 2018 May; 35(3):210-217. PubMed ID: 29560765
[TBL] [Abstract][Full Text] [Related]
6. Impact of mucosal barrier injury laboratory-confirmed bloodstream infection (MBI-LCBI) on central line-associated bloodstream infections (CLABSIs) in department of hematology at single university hospital in Japan.
Kato Y; Hagihara M; Kurumiya A; Takahashi T; Sakata M; Shibata Y; Kato H; Shiota A; Watanabe H; Asai N; Koizumi Y; Yamagishi Y; Mikamo H
J Infect Chemother; 2018 Jan; 24(1):31-35. PubMed ID: 29066217
[TBL] [Abstract][Full Text] [Related]
7. The Centers for Disease Control and Prevention definition of mucosal barrier injury-associated bloodstream infection improves accurate detection of preventable bacteremia rates at a pediatric cancer center in a low- to middle-income country.
Torres D; González ML; Loera A; Aguilera M; Relyea G; Aristizabal P; Caniza MA
Am J Infect Control; 2016 Apr; 44(4):432-7. PubMed ID: 26775931
[TBL] [Abstract][Full Text] [Related]
8. Grading bloodstream infection risk using citrulline as a biomarker of intestinal mucositis in patients receiving intensive therapy.
de Mooij CEM; van der Velden WJFM; de Haan AFJ; Fazel S; van Groningen LFJ; Blijlevens NMA
Bone Marrow Transplant; 2022 Sep; 57(9):1373-1381. PubMed ID: 35661156
[TBL] [Abstract][Full Text] [Related]
9. Severity of acute gastrointestinal graft-vs-host disease is associated with incidence of bloodstream infection after adult allogeneic hematopoietic stem cell transplantation.
Modi A; Rybicki L; Majhail NS; Mossad SB
Transpl Infect Dis; 2020 Feb; 22(1):e13217. PubMed ID: 31769584
[TBL] [Abstract][Full Text] [Related]
10. Chlorhexidine Gluconate Bathing Reduces the Incidence of Bloodstream Infections in Adults Undergoing Inpatient Hematopoietic Cell Transplantation.
Giri VK; Kegerreis KG; Ren Y; Bohannon LM; Lobaugh-Jin E; Messina JA; Matthews A; Mowery YM; Sito E; Lassiter M; Saullo JL; Jung SH; Ma L; Greenberg M; Andermann TM; van den Brink MRM; Peled JU; Gomes ALC; Choi T; Gasparetto CJ; Horwitz ME; Long GD; Lopez RD; Rizzieri DA; Sarantopoulos S; Chao NJ; Allen DH; Sung AD
Transplant Cell Ther; 2021 Mar; 27(3):262.e1-262.e11. PubMed ID: 33781532
[TBL] [Abstract][Full Text] [Related]
11. Mucosal Barrier Injury Laboratory-Confirmed Bloodstream Infections (MBI-LCBI): Descriptive Analysis of Data Reported to National Healthcare Safety Network (NHSN), 2013.
Epstein L; See I; Edwards JR; Magill SS; Thompson ND
Infect Control Hosp Epidemiol; 2016 Jan; 37(1):2-7. PubMed ID: 26456954
[TBL] [Abstract][Full Text] [Related]
12. Incidence, risk factors, and outcome of blood stream infections during the first 100 days post-pediatric allogeneic and autologous hematopoietic stem cell transplantations.
Youssef A; Hafez H; Madney Y; Elanany M; Hassanain O; Lehmann LE; El Haddad A
Pediatr Transplant; 2020 Feb; 24(1):e13610. PubMed ID: 31682054
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology of bloodstream infections after myeloablative and non-myeloablative allogeneic hematopoietic stem cell transplantation: A single-center cohort study.
Gjaerde LI; Moser C; Sengeløv H
Transpl Infect Dis; 2017 Oct; 19(5):. PubMed ID: 28561378
[TBL] [Abstract][Full Text] [Related]
14. Mucosal barrier injury-associated bloodstream infections in pediatric oncology patients.
Hakim H; Billett AL; Xu J; Tang L; Richardson T; Winkle C; Werner EJ; Hord JD; Bundy DG; Gaur AH;
Pediatr Blood Cancer; 2020 Aug; 67(8):e28234. PubMed ID: 32386095
[TBL] [Abstract][Full Text] [Related]
15. Mortality after bloodstream infections in allogeneic haematopoietic stem cell transplant (HSCT) recipients.
Mikulska M; Del Bono V; Bruzzi P; Raiola AM; Gualandi F; Van Lint MT; Bacigalupo A; Viscoli C
Infection; 2012 Jun; 40(3):271-8. PubMed ID: 22187340
[TBL] [Abstract][Full Text] [Related]
16. A Prospective, Holistic, Multicenter Approach to Tracking and Understanding Bloodstream Infections in Pediatric Hematology-Oncology Patients.
Gaur AH; Bundy DG; Werner EJ; Hord JD; Miller MR; Tang L; Lawlor JP; Billett AL;
Infect Control Hosp Epidemiol; 2017 Jun; 38(6):690-696. PubMed ID: 28399945
[TBL] [Abstract][Full Text] [Related]
17. Incidence, Etiology, Risk Factors, and Outcomes of Bloodstream Infection after a Second Hematopoietic Stem Cell Transplantation.
Ohta T; Ueno T; Uehara Y; Yokoyama T; Nakazawa M; Sato Y; Uchida Y; Ohno Y; Sugio Y
Intern Med; 2023 Nov; 62(22):3305-3316. PubMed ID: 37032079
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for pre- and post-engraftment bloodstream infections after allogeneic hematopoietic stem cell transplantation.
Kikuchi M; Akahoshi Y; Nakano H; Ugai T; Wada H; Yamasaki R; Sakamoto K; Kawamura K; Ishihara Y; Sato M; Ashizawa M; Terasako-Saito K; Kimura S; Yamazaki R; Kanda J; Kako S; Nishida J; Kanda Y
Transpl Infect Dis; 2015 Feb; 17(1):56-65. PubMed ID: 25580541
[TBL] [Abstract][Full Text] [Related]
19. Incidence, risk factors, and outcome of bloodstream infections during the pre-engraftment phase in 521 allogeneic hematopoietic stem cell transplantations.
Blennow O; Ljungman P; Sparrelid E; Mattsson J; Remberger M
Transpl Infect Dis; 2014 Feb; 16(1):106-14. PubMed ID: 24372809
[TBL] [Abstract][Full Text] [Related]
20. The incidence, risk factors and outcomes of early bloodstream infection in patients with malignant hematologic disease after unrelated cord blood transplantation: a retrospective study.
Ge J; Yang T; Zhang L; Zhang X; Zhu X; Tang B; Wan X; Tong J; Song K; Yao W; Sun G; Sun Z; Liu H
BMC Infect Dis; 2018 Dec; 18(1):654. PubMed ID: 30545330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
